Previous in vivo studies have demonstrated promising effects of the demethylating agent 2′-deoxy-5-azacytidine (DAC) in restoring MLH1 expression and reversing resistance to chemotherapies in ovarian cancer [52]. This evidence concerns the gene MLH1 and ovarian cancer.